Published in Vaccine Weekly, May 8th, 2002
"These findings validate our decision to accelerate the clinical development programs for our IMiD and SelCID pipelines in cancer," said David I. Stirling, PhD, chief scientific officer of Celgene Corp. "These data also provide valuable mechanistic insight as to how these two classes of orally available, anticancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.